Workflow
Gilead Ups 2025 Outlook, Eyes Lenacapavir Launch For HIV Prevention
GILDGilead(GILD) Benzinga·2025-02-12 20:22

Core Insights - Gilead Sciences reported fourth-quarter 2024 adjusted EPS of 1.90,exceedingtheconsensusestimateof1.90, exceeding the consensus estimate of 1.70, with sales rising 6% year-over-year to 7.57billion,surpassingtheconsensusof7.57 billion, surpassing the consensus of 7.14 billion [1][2] Sales Performance - HIV sales increased by 16% to 5.45billion,drivenbydemand,higherrealizedprices,andfavorableinventorydynamics[1]−Biktarvysalesrosefrom5.45 billion, driven by demand, higher realized prices, and favorable inventory dynamics [1] - Biktarvy sales rose from 3.12 billion to 3.8billion,whileliverdiseasesalesincreasedby43.8 billion, while liver disease sales increased by 4% to 719 million, supported by a strong Livdelzi launch and increased HBV/HDV demand [2] Dividend and Guidance - Gilead increased its quarterly cash dividend by 2.6% to 0.79pershare[2]−Thecompanyexpects2025adjustedEPStobebetween0.79 per share [2] - The company expects 2025 adjusted EPS to be between 7.70 and 8.10,comparedtotheconsensusof8.10, compared to the consensus of 7.58, and sales to range from 28.2billionto28.2 billion to 28.6 billion, against a consensus of 28.42billion[3]FutureProspects−GileadplanstolaunchlenacapavirforHIVPrEPinSummer2025,whichisexpectedtoenhanceitspositioninthePrEPmarketandimprovepatientadherence[4][5]−AnalystsfromPiperSandlerandGoldmanSachsexpressoptimismregardingGilead′supcominglenacapavirlaunchanditspotentialimpactonrevenue[4][5]AnalystSentiment−NeedhammaintainsaHoldratingonGilead,citingbalancedrisk/rewardatcurrentlevels,butisgrowingmoreoptimisticduetostrongHIVbusinessperformanceandimprovingprofitmargins[6][7]−Gilead′sstockroseby7.7328.42 billion [3] Future Prospects - Gilead plans to launch lenacapavir for HIV PrEP in Summer 2025, which is expected to enhance its position in the PrEP market and improve patient adherence [4][5] - Analysts from Piper Sandler and Goldman Sachs express optimism regarding Gilead's upcoming lenacapavir launch and its potential impact on revenue [4][5] Analyst Sentiment - Needham maintains a Hold rating on Gilead, citing balanced risk/reward at current levels, but is growing more optimistic due to strong HIV business performance and improving profit margins [6][7] - Gilead's stock rose by 7.73% to 103.57 following the earnings report [7]